瑞康医药：5月15日召开业绩说明会，投资者参与

Core Viewpoint - 瑞康医药 is actively engaging in strategic acquisitions and capital raising to enhance its position in the medical device sector and address future challenges in the healthcare industry [1][2][3] Group 1: Company Actions and Strategies - 瑞康医药 announced a share buyback plan using bank loans and its own funds, with the intention to use the repurchased shares for employee stock ownership plans or equity incentives within three years [1] - The company is acquiring 浙江衡玖医疗器械有限责任公司 to expand its footprint in the high-end medical equipment sector, specifically targeting advanced imaging systems [1] - The issuance of shares to specific investors is aligned with the company's strategic development needs and complies with relevant regulations, providing efficient funding support for operations [2] Group 2: Financial Performance - In Q1 2025, 瑞康医药 reported a main revenue of 1.757 billion yuan, a year-on-year decrease of 12.98%, and a net profit attributable to shareholders of 14.171 million yuan, down 6.58% [3] - The company's net profit excluding non-recurring items was 10.034 million yuan, reflecting a significant decline of 44.75% year-on-year [3] - The company's debt ratio stands at 64.53%, with investment income of 5.233 million yuan and financial expenses amounting to 49.171 million yuan, resulting in a gross margin of 13.85% [3] Group 3: Future Outlook - 瑞康医药 is considering entering the elderly care industry as a response to the aging population, indicating a strategic focus on addressing future healthcare needs [3]